No Data
Shareholder Xiangtang Group has cumulatively reduced its shareholding by 23.5354 million shares.
Staidson (300204.SZ) announced that the company received a notification from the shareholder Xiangtang Group Co., Ltd. (referred to as "Xiangtang Group")...
Shu Taishen: Report for the third quarter of 2024
Staidson (300204.SZ) released its performance for the first three quarters, with a net loss of 9.365 million yuan.
Staidson (300204.SZ) released the report for the first three quarters of 2024, during the reporting period, the company achieved revenue of 2...
Staidson (300204.SZ): the net loss in the first three quarters was 9.365 million yuan
Staidson (300204.SZ) announced its third quarter report for 2024 on October 24th. The company achieved revenue of 0.261 billion yuan in the first three quarters, a year-on-year decrease of 4.91%; the net income attributable to shareholders of the listed company was -9.36496 million yuan; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -13.3028 million yuan; and the basic earnings per share was -0.02 yuan.
staidson(300204.SZ): The first subject in the Phase I clinical trial of STSP-0902 eye drops was dosed.
Staidson (300204.SZ) announced that the company received the approval from the National Pharmaceutical Regulatory Authority in July 2024...
Staidson (300204.SZ): The compound polyethylene glycol (3350) electrolyte Vitamin C powder obtained the pharmaceutical registration certificate.
staidson (300204.SZ) announcement, recently, the company has received the National Pharmaceutical Administration (referred to as the National Pharmaceutical...
No Data
No Data